Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Abiomed, Inc. stock logo
ABMD
Abiomed
$381.02
$380.55
$219.85
$381.99
$17.18B1.4611,028 shs258 shs
Fresenius SE & Co. stock logo
FSNUY
Fresenius SE & Co.
$12.57
+0.5%
$12.21
$7.59
$12.97
N/A0.7530,378 shs18,417 shs
NovoCure Limited stock logo
NVCR
NovoCure
$17.88
+0.4%
$17.70
$14.17
$34.13
$1.98B0.721.14 million shs1.16 million shs
Insulet Corporation stock logo
PODD
Insulet
$299.99
-4.5%
$300.32
$173.00
$329.33
$22.11B1.35716,587 shs1.40 million shs
Teleflex Incorporated stock logo
TFX
Teleflex
$121.50
+2.7%
$124.19
$115.94
$249.91
$5.23B1.08630,065 shs735,527 shs
Investing Strategies To Help Grow Your Retirement Income Cover

Need to stretch out your 401K or Roth IRA plan? Use these time-tested investing strategies to grow the monthly retirement income that your stock portfolio generates.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Abiomed, Inc. stock logo
ABMD
Abiomed
0.00%0.00%0.00%0.00%0.00%
Fresenius SE & Co. stock logo
FSNUY
Fresenius SE & Co.
0.00%+2.71%+2.36%+17.24%+66.36%
NovoCure Limited stock logo
NVCR
NovoCure
-1.11%+7.16%-5.67%+1.60%+3.91%
Insulet Corporation stock logo
PODD
Insulet
+0.35%+2.12%-3.18%+19.38%+55.69%
Teleflex Incorporated stock logo
TFX
Teleflex
-1.01%+0.08%-3.26%-15.64%-43.80%
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Abiomed, Inc. stock logo
ABMD
Abiomed
1.5309 of 5 stars
0.00.00.04.30.61.71.9
Fresenius SE & Co. stock logo
FSNUY
Fresenius SE & Co.
N/AN/AN/AN/AN/AN/AN/AN/A
NovoCure Limited stock logo
NVCR
NovoCure
3.7668 of 5 stars
3.31.00.04.53.11.70.0
Insulet Corporation stock logo
PODD
Insulet
4.1915 of 5 stars
2.43.00.04.93.00.81.9
Teleflex Incorporated stock logo
TFX
Teleflex
4.6424 of 5 stars
3.04.02.53.92.31.71.3
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Abiomed, Inc. stock logo
ABMD
Abiomed
0.00
N/AN/AN/A
Fresenius SE & Co. stock logo
FSNUY
Fresenius SE & Co.
3.33
BuyN/AN/A
NovoCure Limited stock logo
NVCR
NovoCure
2.67
Moderate Buy$32.8383.63% Upside
Insulet Corporation stock logo
PODD
Insulet
2.83
Moderate Buy$321.007.00% Upside
Teleflex Incorporated stock logo
TFX
Teleflex
2.09
Hold$164.6335.49% Upside

Current Analyst Ratings Breakdown

Latest TFX, NVCR, PODD, ABMD, and FSNUY Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
6/27/2025
NovoCure Limited stock logo
NVCR
NovoCure
Piper Sandler
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingOverweight ➝ Overweight$34.00
6/16/2025
Insulet Corporation stock logo
PODD
Insulet
Truist Financial
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Initiated CoverageBuy$365.00
5/30/2025
Insulet Corporation stock logo
PODD
Insulet
The Goldman Sachs Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Initiated CoverageBuy$380.00
5/27/2025
Insulet Corporation stock logo
PODD
Insulet
Raymond James Financial
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingOutperform ➝ Outperform$328.00 ➝ $360.00
5/22/2025
Insulet Corporation stock logo
PODD
Insulet
Citigroup
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$320.00 ➝ $380.00
5/16/2025
Insulet Corporation stock logo
PODD
Insulet
Sanford C. Bernstein
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingOutperform ➝ Outperform
5/15/2025
Fresenius SE & Co. stock logo
FSNUY
Fresenius SE & Co.
Morgan Stanley
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingOverweight ➝ Overweight
5/13/2025
Insulet Corporation stock logo
PODD
Insulet
Wolfe Research
Subscribe to MarketBeat All Access for the recommendation accuracy rating
UpgradePeer Perform ➝ Outperform$350.00
5/9/2025
Insulet Corporation stock logo
PODD
Insulet
Oppenheimer
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetOutperform ➝ Outperform$312.00 ➝ $324.00
5/5/2025
Teleflex Incorporated stock logo
TFX
Teleflex
Truist Financial
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetHold ➝ Hold$140.00 ➝ $137.00
5/5/2025
Teleflex Incorporated stock logo
TFX
Teleflex
Morgan Stanley
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetOverweight ➝ Overweight$191.00 ➝ $173.00
(Data available from 7/1/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Abiomed, Inc. stock logo
ABMD
Abiomed
$1.03B16.65$5.09 per share74.88$33.03 per share11.54
Fresenius SE & Co. stock logo
FSNUY
Fresenius SE & Co.
$23.63BN/A$1.30 per share9.69$9.83 per shareN/A
NovoCure Limited stock logo
NVCR
NovoCure
$605.22M3.29N/AN/A$3.33 per share5.37
Insulet Corporation stock logo
PODD
Insulet
$2.07B10.19$4.24 per share70.82$17.27 per share17.37
Teleflex Incorporated stock logo
TFX
Teleflex
$3.05B1.76$26.02 per share4.67$92.11 per share1.32
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Abiomed, Inc. stock logo
ABMD
Abiomed
$136.51M$5.8265.4769.783.3324.84%14.77%13.32%N/A
Fresenius SE & Co. stock logo
FSNUY
Fresenius SE & Co.
$509.67M$0.1966.1613.66N/A1.92%9.06%4.17%8/6/2025 (Estimated)
NovoCure Limited stock logo
NVCR
NovoCure
-$168.63M-$1.51N/AN/AN/A-26.41%-45.46%-13.34%7/24/2025 (Estimated)
Insulet Corporation stock logo
PODD
Insulet
$418.30M$5.5653.9660.362.8018.29%22.25%8.29%8/6/2025 (Estimated)
Teleflex Incorporated stock logo
TFX
Teleflex
$69.68M$3.1738.338.001.854.96%14.73%8.79%7/30/2025 (Estimated)

Latest TFX, NVCR, PODD, ABMD, and FSNUY Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
7/24/2025Q2 2025
NovoCure Limited stock logo
NVCR
NovoCure
-$0.40N/AN/AN/A$153.87 millionN/A
5/8/2025Q1 2025
Insulet Corporation stock logo
PODD
Insulet
$0.81$1.02+$0.21$0.50$543.20 million$569.00 million
5/7/2025Q1 2025
Fresenius SE & Co. stock logo
FSNUY
Fresenius SE & Co.
$0.2170$0.23+$0.0130$0.11$5.41 billion$5.92 billion
5/1/2025Q1 2025
Teleflex Incorporated stock logo
TFX
Teleflex
$2.88$2.91+$0.03$2.07$699.37 million$700.67 million
4/24/2025Q1 2025
NovoCure Limited stock logo
NVCR
NovoCure
-$0.47-$0.31+$0.16-$0.31$147.57 million$154.99 million
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Abiomed, Inc. stock logo
ABMD
Abiomed
N/AN/AN/AN/AN/A
Fresenius SE & Co. stock logo
FSNUY
Fresenius SE & Co.
$0.191.51%N/A100.00%N/A
NovoCure Limited stock logo
NVCR
NovoCure
N/AN/AN/AN/AN/A
Insulet Corporation stock logo
PODD
Insulet
N/AN/AN/AN/AN/A
Teleflex Incorporated stock logo
TFX
Teleflex
$1.361.12%N/A42.90%N/A

Latest TFX, NVCR, PODD, ABMD, and FSNUY Dividends

AnnouncementCompanyPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
5/12/2025
Teleflex Incorporated stock logo
TFX
Teleflex
quarterly$0.341.09%5/20/20255/20/20256/16/2025
5/22/2025
Fresenius SE & Co. stock logo
FSNUY
Fresenius SE & Co.
$0.18271.48%5/27/20255/28/20256/4/2025
(Data available from 1/1/2013 forward)
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Abiomed, Inc. stock logo
ABMD
Abiomed
N/A
7.93
7.17
Fresenius SE & Co. stock logo
FSNUY
Fresenius SE & Co.
0.50
1.43
1.11
NovoCure Limited stock logo
NVCR
NovoCure
0.27
1.47
1.41
Insulet Corporation stock logo
PODD
Insulet
1.21
4.47
3.63
Teleflex Incorporated stock logo
TFX
Teleflex
0.44
2.28
1.32

Institutional Ownership

CompanyInstitutional Ownership
Abiomed, Inc. stock logo
ABMD
Abiomed
94.48%
Fresenius SE & Co. stock logo
FSNUY
Fresenius SE & Co.
N/A
NovoCure Limited stock logo
NVCR
NovoCure
84.61%
Insulet Corporation stock logo
PODD
Insulet
N/A
Teleflex Incorporated stock logo
TFX
Teleflex
95.62%

Insider Ownership

CompanyInsider Ownership
Abiomed, Inc. stock logo
ABMD
Abiomed
2.50%
Fresenius SE & Co. stock logo
FSNUY
Fresenius SE & Co.
N/A
NovoCure Limited stock logo
NVCR
NovoCure
5.52%
Insulet Corporation stock logo
PODD
Insulet
0.39%
Teleflex Incorporated stock logo
TFX
Teleflex
1.40%
CompanyEmployeesShares OutstandingFree FloatOptionable
Abiomed, Inc. stock logo
ABMD
Abiomed
2,00345.09 million43.96 millionOptionable
Fresenius SE & Co. stock logo
FSNUY
Fresenius SE & Co.
176,486N/AN/ANot Optionable
NovoCure Limited stock logo
NVCR
NovoCure
1,488111.49 million105.33 millionOptionable
Insulet Corporation stock logo
PODD
Insulet
3,90070.38 million70.10 millionOptionable
Teleflex Incorporated stock logo
TFX
Teleflex
14,10044.19 million43.57 millionOptionable

Recent News About These Companies

Teleflex closes deal with BIOTRONIK
Teleflex (NYSE:TFX) Stock Rating Lowered by Wall Street Zen
Zacks Research Has Bearish Forecast for Teleflex Q2 Earnings
Teleflex (NYSE:TFX) Upgraded to "Buy" at Wall Street Zen
Brokerages Set Teleflex Incorporated (NYSE:TFX) PT at $164.63

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All Headlines
Abiomed stock logo

Abiomed NASDAQ:ABMD

Abiomed, Inc. engages in the research, development, and sale of medical devices to assist or replace the pumping function of the failing heart. It also provides a continuum of care to heart failure patients. The company offers Impella 2.5, a percutaneous micro heart pump with integrated motor and sensors; and Impella CP, a device for use by interventional cardiologists to support patients in the cath lab, as well as by cardiac surgeons in the heart surgery suite. It also provides Impella 5.0, Impella LD, and Impella 5.5, which are percutaneous micro heart pumps with integrated motors and sensors for use primarily in the heart surgery suite; Impella RP, a percutaneous catheter-based axial flow pump; Impella SmartAssist platform that includes optical sensor technology for improved pump positioning and the use of algorithms that enable improved native heart assessment during the weaning process; Impella Connect, a cloud-based technology that enables secure and remote viewing of the automated impella controller for physicians and hospital staffs; and OXY-1 System, a portable external respiratory assistance device. In addition, the company is developing Impella ECP, a pump for blood flow of greater than three liters per minute; Impella XR Sheath, a sheath that expands and recoils allowing small bore access and closure with Impella heart pumps; Impella BTR, a percutaneous micro heart pump with integrated motors and sensors; and preCARDIA, a catheter-mounted superior vena cava therapy system designed to rapidly treat acutely decompensated heart failure. Abiomed, Inc. sells its products through direct sales and clinical support personnel in the Germany, France, United States, Japan, Europe, Canada, Latin America, the Asia-Pacific, and the Middle East. The company was founded in 1981 and is headquartered in Danvers, Massachusetts. As of December 22, 2022, Abiomed, Inc. operates as a subsidiary of Johnson & Johnson.

Fresenius SE & Co. stock logo

Fresenius SE & Co. OTCMKTS:FSNUY

$12.57 +0.06 (+0.48%)
As of 03:50 PM Eastern

Fresenius SE & Co. KGaA, a health care company, provides products and services for chronically ill patients. It operates through four segments: Fresenius Medical Care, Fresenius Kabi, Fresenius Helios, and Fresenius Vamed. The Fresenius Medical Care segment offers products and services for patients with chronic kidney failure. This segment provides dialyzers, dialysis machines, and related disposable products, as well as dialysis-related services. The Fresenius Kabi segment engages in the therapy and care of critically and chronically ill patients. This segment offers I.V. generic drugs; biosimilar drugs for autoimmune diseases and oncology; enteral and parenteral nutrition products; medical technologies, as well as disposables, infusions pumps, apheresis machines, cell therapy devices, and other products. The Fresenius Helios segment provides clinical and nursing care facilities. The Fresenius Vamed segment provides services for hospitals and other healthcare facilities. This segment also offers operational management of healthcare facilities and provides services to patients. The company was formerly known as Fresenius SE and changed its name to Fresenius SE & Co. KGaA in January 2011. Fresenius SE & Co. KGaA was founded in 1912 and is headquartered in Bad Homburg vor der Höhe, Germany.

NovoCure stock logo

NovoCure NASDAQ:NVCR

$17.88 +0.08 (+0.45%)
Closing price 04:00 PM Eastern
Extended Trading
$17.90 +0.03 (+0.14%)
As of 07:50 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

NovoCure Limited, an oncology company, engages in the development, manufacture, and commercialization of tumor treating fields (TTFields) devices for the treatment of solid tumor cancers in the United States, Germany, Japan, Greater China, and internationally. The company's TTFields devices include Optune Gio and Optune Lua. It also has ongoing clinical trials investigating TTFields in brain metastases, gastric cancer, glioblastoma, liver cancer, non-small cell lung cancer, pancreatic cancer, and ovarian cancer. NovoCure Limited was incorporated in 2000 and is headquartered in Saint Helier, Jersey.

Insulet stock logo

Insulet NASDAQ:PODD

$299.99 -14.19 (-4.52%)
Closing price 04:00 PM Eastern
Extended Trading
$299.94 -0.05 (-0.02%)
As of 07:20 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes. The company's Omnipod platform includes the Omnipod 5 Automated Insulin Delivery System (Omnipod 5) which includes a proprietary AID algorithm embedded in the Pod that integrates with a third-party continuous glucose monitor to obtain glucose values through wireless bluetooth communication; Omnipod DASH that features a bluetooth enabled Pod that is controlled by a smartphone-like Personal Diabetes Manager with a color touch screen user interface; and Omnipod GO, a standalone, wearable, insulin delivery system that provides a fixed rate of continuous rapid-acting insulin for 72 hours. The company sells its products primarily through independent distributors and pharmacy channels, as well as directly in the United States, Canada, Europe, the Middle East, Australia, and internationally. Insulet Corporation was incorporated in 2000 and is headquartered in Acton, Massachusetts.

Teleflex stock logo

Teleflex NYSE:TFX

$121.50 +3.14 (+2.65%)
Closing price 03:59 PM Eastern
Extended Trading
$121.78 +0.28 (+0.23%)
As of 06:11 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Teleflex Incorporated designs, develops, manufactures, and supplies single-use medical devices for common diagnostic and therapeutic procedures in critical care and surgical applications worldwide. The company provides vascular access products that comprise Arrow branded catheters, catheter navigation and tip positioning systems, and intraosseous access systems for the administration of intravenous therapies, the measurement of blood pressure, and the withdrawal of blood samples through a single puncture site. It also offers interventional products, which consists of various coronary catheters, structural heart support devices, and peripheral intervention and mechanical circulatory support platform that are used by interventional cardiologists and radiologists, and vascular surgeons; and Arrow branded pumps and catheters, Guideline, Turnpike, and Trapliner catheters, the Manta Vascular Closure, and Arrow Oncontrol devices. The company provides anesthesia products, such as airway and pain management products to support hospital, emergency medicine, and military channels; and surgical products, including metal and polymer ligation clips, and fascial closure surgical systems that are used in laparoscopic surgical procedures, percutaneous surgical systems, and other surgical instruments. It also offers interventional urology products comprising the UroLift System, an invasive technology for treating lower urinary tract symptoms due to benign prostatic hyperplasia; respiratory products, including oxygen and aerosol therapies, spirometry, and ventilation management products for use in various care settings; urology products, such as catheters, urine collectors, and catheterization accessories and products for operative endourology; and bladder management services. The company serves hospitals and healthcare providers, medical device manufacturers, and home care markets. Teleflex Incorporated was incorporated in 1943 and is headquartered in Wayne, Pennsylvania.